InMed Pharmaceuticals Inc. (INM)
NASDAQ: INM · Real-Time Price · USD
2.110
+0.020 (0.96%)
At close: Sep 5, 2025, 4:00 PM
2.150
+0.040 (1.90%)
After-hours: Sep 5, 2025, 4:52 PM EDT
InMed Pharmaceuticals Revenue
InMed Pharmaceuticals had revenue of $1.26M in the quarter ending March 31, 2025, with 7.59% growth. This brings the company's revenue in the last twelve months to $4.92M, down -12.53% year-over-year. In the fiscal year ending June 30, 2024, InMed Pharmaceuticals had annual revenue of $4.60M with 11.18% growth.
Revenue (ttm)
$4.92M
Revenue Growth
-12.53%
P/S Ratio
0.31
Revenue / Employee
$378,538
Employees
13
Market Cap
4.22M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Jun 30, 2024 | 4.60M | 462.17K | 11.18% |
Jun 30, 2023 | 4.14M | 3.05M | 279.61% |
Jun 30, 2022 | 1.09M | - | - |
Jun 30, 2021 | - | - | - |
Jun 30, 2020 | - | - | - |
Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
INM News
- 1 day ago - InMed to Participate in the H.C. Wainwright 27th Annual Global Investment Conference - Newsfile Corp
- 5 weeks ago - InMed to Present INM-901 Data at Alzheimer's Association International Conference (AAIC) 2025 - Newsfile Corp
- 2 months ago - InMed Pharmaceuticals Announces Closing of $5 Million Private Placement Priced At-the-Market under Nasdaq Rules - Newsfile Corp
- 2 months ago - InMed Pharmaceuticals Announces $5 Million Private Placement Priced At-the-Market Under Nasdaq Rules - Newsfile Corp
- 2 months ago - InMed's INM-901 Significantly Reduces Neuroinflammation in Alzheimer's Disease Ex Vivo Study - Newsfile Corp
- 3 months ago - InMed Appoints CBIZ as New Auditor in Connection with CBIZ's Acquisition of Marcum's Attest Business, Provides Update on Special Meeting and Makes Modifications to Existing SEPA - Newsfile Corp
- 4 months ago - InMed Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update - Newsfile Corp
- 7 months ago - InMed Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update - Newsfile Corp